50 Presentations from Top Pharma at PEGS Europe 2018

How Do We Assemble an Effective and Efficient Protein Production Toolbox?
Richard Altman, MS, Scientist, Protein Technologies, Amgen

Purification Technologies to Tackle Complex Therapeutic Proteins during Lead Selection
Philipp Amsler, MSc, Functional Lead, Integrated Biologics Profiling, Novartis Institutes for BioMedical Research

CD20 TCB (RG6026), a Novel "2:1" T-Cell Bispecific Antibody for the Treatment of B-Cell Malignancies
Marina Bacac, PhD, Head, Cancer Immunotherapy, Roche Innovation Center Zurich

Case Studies on How Digital and Automated Solutions Transform the Discovery and Development of Next-Generation Antibodies
Martin Bader, PhD, Head, Biochemical and Analytical Research, Pharma Research and Early Development, Roche

Scale-Down Models for Freezing/Thawing Process to Control Aggregation
Karoline Bechtold-Peters, PhD, Senior Strategy and Technology Leader, Biologics Technical Development & Manufacturing, Novartis Pharma AG

From Antibody-Targeted Toxins to Gene Editing: Disruption of Diphthamide Synthesis Genes and Resulting Toxin Resistance as a Robust Technology for Quantifying and Optimizing CRISPR/Cas9 Approaches
Ulrich Brinkmann, PhD, Expert Scientist, Molecular Engineering, Roche

Novel Approaches to Target the Tumor Stroma for Cancer Immunotherapy
Christina Claus, PhD, Senior Scientist, Oncology, Immunotherapy, pRED, Roche Innovation Center, Zurich

Making and Testing the Human Secretome
Rick Davies, PhD, Associate Director, Discovery Biology, AstraZeneca Pharmaceuticals

Discovering Antibodies against Challenging Epitopes and Challenging Antigens
Ruud de Wildt, PhD, Director, Head of Lead Discovery, Biopharm, GlaxoSmithKline

Development of Effective Combination Therapies for Immuno-Oncology
Rakesh Dixit, PhD, Vice President, Safety Assessment, MedImmune, Inc.

Characterization of Variants of a Clinical Antibody Candidate Using Alternative and Novel Separation Methods
David Eisen, PhD, Scientist, Technical R&D, Technical Development Biosimilars, Novartis

Challenging Molecules in Biopharmaceutical Development: Innovative Tools for Cell Line Development
Martin Gamer, PhD, Associate Director, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG

Multiple Mechanism of Ligand Blocking by Antibodies
Fernando Garces, PhD, Senior Scientist, Therapeutic Discovery, Amgen

HOS in QC Environment - Could Native Peptide Mapping Support/Replace Bioassay for Stability Monitoring of Biopharmaceuticals?
Michel Degueldre, Scientist, Analytical Sciences Biologicals, UCB Pharma SA

DVD-Ig Platform: Clinical Lessons and Future Directions
Tariq Ghayur, PhD, Distinguished Research Fellow, Foundational Immunology, AbbVie Bioresearch Center

Quantification and Degradation Monitoring of PS80 in One Single Analysis Using QDa Mass Detector
Pierre Guibal, PhD, Deputy Head, Analytical Development, BioAnalytics, Sanofi

New Formats, New Experiences - DSP Feedback for Carefully Selecting a Molecule for Development
Maximilian Hartl, PhD, Senior Scientist, Roche Pharma Research & Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich

Antibody Discovery at Bayer beyond Oncology
Rene Hoet, PhD, Head, Antibody Lead Discovery, Bayer AG

Using Physics-Based Simulations to Understand the Determinants of Viscosity in Concentrated Antibody Solutions
Saeed Izadi, PhD, Scientist, Early Stage Pharmaceutical Development, Genentech, Inc.

New Insights into the Mechanistics of Antibody Pharmacokinetics
Hubert Kettenberger, PhD, Senior Principal Scientist, Large Molecule Research, Roche Innovation Center Munich

Adaptive Automated Membrane Protein Purification Using AkTA Avant
Jonas Lee, PhD, Scientist, Protein Technologies, Amgen, Inc.

Optimising Developability - Learning from Experimental Data
Lars Linden, PhD, Head, Protein Biochemistry, Biologics-Research, Cell and Protein Science, Bayer AG

Developing, Qualifying and Validating Analytical Methods for Novel Biologics
Declan Lowney, MSc, Associate Director, Analytical Development, Janssen R&D

Development of Novel Interleukin-2 Variants for Immunotherapy of Cancer and Autoimmune Diseases
Ekkehard Moessner, PhD, Head, Protein Engineering, Large Molecules Research, Roche Innovation Center Zurich

Developability Strategies to Support Fast to FTIH Studies
Mike Molloy, MSc, Director, Analytical and Characterisation, Biopharm Process Research, GlaxoSmithKline

Studies with the Oncolytic Virus VSV-GP, Cancer Vaccines and Immune-Modulation: The Yin and the Yang
Philipp Mueller, PhD, Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG

Update on BiTE® Antibody Constructs Currently in Clinical Development
Virginie Nägele, PhD, Senior Scientist, BiTE Technology, Amgen Research (Munich) GmbH

Discovery of Novel Enhancers for Antibody Expression by Transcriptomics-Based Pathway Analysis
Markus Neubauer, PhD, Head, Cell Culture Research, Pharma Research & Development, Roche Innovation Center Munich

Phage Display as a Tool for Bispecific Antibody Generation
Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.

Multiple Attribute Monitoring - Optimization of Automated Sample Preparation
Anja Pfenninger, PhD, Lab Head, Mass Spectrometry, Bioanalytics/Biopharmaceutical Development, Sanofi

New Payloads for Antibody-Drug Conjugates
Thomas Pillow, PhD, Senior Scientist, Discovery Chemistry, Genentech, Inc.

Broad Impact of anti-PD-LI on the Tumour Microenvironment
Yan Qu, PhD, Senior Principal Scientist, Rinat Pfizer

Recombinant Human B Cell Repertoires Enable Screening for Rare, Specific, and Natively Paired Antibodies
Saravanan Rajan, PhD, Scientist II, Antibody Discovery & Protein Engineering, MedImmune

Establishing High Throughput, Low Protein Consuming Biophysical Platform for Biologics Characterization
Saskia Villinger, PhD, Scientist, Formulation & Process Development / Biologics Drug Product Development, Sanofi

The Effect of New Stabilizers in Downstream mAb Process Intermediates
Irina Ramos, PhD, Downstream Process Scientist, MedImmune, Inc.

Energetic Epitope Mapping of an Antibody/Interleukin-23 Interaction
Lumelle A. Schneeweis, PhD, Protein Science, Molecular Discovery Technologies, Bristol-Myers Squibb

Utility of PK-PD Modeling and Simulation (M&S) in the Discovery and Development of Next-Generation Immunoconjugates (ICs) for Cancer Therapy
Aman P. Singh, PhD, PK-PD Scientist/Biologics Development Leader, Janssen Biotherapeutics

Development of Novel Fully Human Bispecific Antibodies for Oncology
Eric Smith, PhD, Director, Bispecific Antibodies, Regeneron, Inc.

Engineering of a T-Cell Dependent Bispecific to Broaden the Therapeutic Index for Solid Tumors
Christoph Spiess, PhD, Senior Scientist, Antibody Engineering, Genentech, Inc.

A Case Study in Adaptability: Exemplification of the Power of UCB's Core Discovery Platform through the Discovery of a Potent Anti-Tau Antibody
Dale Starkie, MSc, Senior Scientist, UCB Celltech

Protein-Excipient Interactions Evaluated via NMR Studies in Polysorbate-Based Multi-Dose Protein Formulations: Influence on Antimicrobial Efficacy and Potential Study Approach
Riccardo Torosantucci, PhD, Lab Head, Formulation Development, Pharmaceutical Development Biologics, Sanofi-Aventis Deutschland GmbH

Productive Common Light Chain Libraries Yield Diverse Panels of High Affinity Bispecific Antibodies
Thomas Van Blarcom, PhD, Associate Research Fellow, Protein Engineering, Pfizer, Inc.

Streamlining Monoclonal CHO Cell Line Generation Using Droplet Microfluidics
James White, Research Scientist, Protein Sciences, UCB Biopharma

Rational Design of Monoclonal Antibodies with High Developability Potential
Adriana-Michelle Wolf Pérez, MSc, PhD Student, Large Protein Biophysics, Novo Nordisk

Structure-Function Characterization of Sulfated Glycans in Recombinant Idursulfase
Bernice Yeung, PhD, Global Head of Characterization, Analytical Development, Shire

Efficient Identification of mAb Therapeutics with Optimal Developability
Fang Yi, PhD, Principal Scientist, Biologics Discovery Sciences, Janssen Biotherapeutics, Johnson & Johnson

Factors Influencing Biotherapeutic mAb Aggregation
Linda Yi, PhD, Senior Scientist, Analytical Development, Biogen

Development Strategy of Fibril-Prone Peptide Therapeutics: Aggregation Kinetics, Predictive Methods, and Detection Methods
Jingtao Zhang, PhD, Principal Scientist, Pharmaceutical Sciences, Merck & Co.

Discovery of a Cryptic Peptide Binding Site on PCSK9 and Design of Antagonists
Yingnan Zhang, PhD, Senior Scientific Manager, Early Discovery Biochemistry, Genentech, Inc.